Hep C Knowledge Bank

Wang, Y. et. al. (2012). Body mass index and risk of primary liver cancer: a meta-analysis of prospective studies. The Oncologist, 17(11), 1461-1468.

Udell, J. A. et. al. (2012). Does this patient with liver disease have cirrhosis? JAMA, 307(8), 832-842.

Shi KQ. et al. (2012) Interleukin-28B polymorphisms on the SVR in the treatment of naive chronic hepatitis C with pegylated interferon-alpha plus ribavirin: a meta-analysis. Gene, 507(1):27-35.

Rangnekar AS. et al. (2012) Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Alimentary Pharmacology & Therapeutics, 36(2):104-114.

Jia Z. et al. (2012) Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis. PLoS ONE, 7(9):e45698.

Fabrizi F. et al. (2012) Hepatitis C virus infection and kidney disease: a meta-analysis. Clinical Journal of The American Society of Nephrology, 7(4):549-557.

Fabrizi F. et al. (2012) Antiviral therapy for HCV-associated cryoglobulinemic glomerulonephritis: case report and review of the literature. Kidney & Blood Pressure Research, 35(6):687-693.

Chen Y. et al. (2012) Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ribavirin. Alimentary Pharmacology & Therapeutics, 36(2):91-103.

Qin H. et al. (2012) Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials. Clinical Drug Investigation, 32(10):665-672.

Matthews SJ. et al. (2012) Telaprevir: a hepatitis C NS3/4A protease inhibitor. Clinical Therapeutics, 34(9):1857-1882.

Pages